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Seven structural analogues of bradykinin, containing optically-active L- and D-pipecolic 
acid**, were prepared and purified, and their physical constants were determined. 
Slight changes in the structures of known peptide hormones by substituting 
amino acids of similar character for constituent amino acids are very important 
for investigation of the relationship between chemical structure and biological 
activity [1—3]. 
The amino acids substituted may be similar or not; they can be proteinogenic 
or nonproteinogenic. The known tissue hormone bradykinin 
Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg 
can be detected in the brain. Since this hormone contains three proline residues, 
it is easy to get more information by synthesis and biological study of bradykinin 
analogues containing one or more pipecolic acid residues in place of proline. 
Up to now, numerous papers on the substitution of proline by optically-active 
pipecolic acid can be found in the literature of peptide chemistry. This synthesis 
may be achieved both classical and solid phase methods [4]. Among others, peptide 
analogues reported containing optically-active pipecolic acids include collagen 
models [5], oxytocin [6], angiotensin II [7], thyreotropin releasing hormone [8, 9], 
sequence-polypeptide [10] and model peptides [11]. Some others now under pub-
lication [12]. 
In order to fill gaps in the literature, special attention has been paid to the 
peptide chemical application of optically-active pipecolic acids [13]. Subsequently, 
the preparation of different protected and active derivatives of both L- and D-pipe-
colic acid was reported [14, 15] in detail. First, 3-L-pipecolic acid bradykinin appeared 
in the literature [16]; later, our rdsearch group reported 2-L- and 3-D-pipecolic acid 
* Biological Center of the Hungarian Academy of Sciences, Szeged 
** Nomenclature and'abbreviations are those accepted by IUPAC—IUB for peptide chemistry: 
pip = pipecolic acid; Z = benzyloxycarbonyl; BOC = r-butyloxycarbonyl; OMe = methylester; ONb = 
=p-nitro-benzylester. Except for glycine, all proteinogenic amino acids are in the £.-form. 
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Physical properties and analytical 




























































1 all analogous are tabled 
2 A=stepwise condensation, B=fragment condensation 
3 A = s i l i c a gel column, B = Whatman CM 32 CMC-column, a=sys tem 2, b=system 3, 
c = EtOAc-MeOH system, d=0.01—0.5 M ammonium acetate 
4 A=ace t ic acid, D = dimethylformamide 
bradykinin [17] and some fragments of further analogues [18, 19]. In this paper 
we describe the preparation of the following protected and free bradykinins: 
2,7-L-pipecolic acid (1—2), 3,7-L-pipecolic acid (3—4), 2-D-pipecolic acid (5—6), 
7-D-pipecolic acid (7—8), 7-L-pipecolic acid (9—10), 2,3-L-pipecolic acid (11—12) 
and 2,3,7-L-pipecolic acid bradykinins (13—14). 
The first four analogues were synthesized in a stepwise manner, the others 
by a fragment condensation method. The biological data of these analogues will 
be published elsewhere [20]. 
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Table I 




C = 1 
T = 24 °CJ 
F o r m u l a 
(Mol. weight) 
Elemental analysis (N%) 
Calc. Found 




- 4 7 ° D 
- 8 0 ° A 
CßI H 8 30 1 7 N17 
(1326.5) 
C 5 8 H „ O U N 1 5 X 3 CH3COOH 
(1268.3) 
17.9 17.7 
Arg 1.82 Pro 1.02 Pip 1.9 
Gly 1.0 Pre 1.97 Ser 0.88 
132—140 
176—186 
- 5 0 ° D 
- 8 0 ° A 
C6IH8 301 7N1 7 
(1326.5) 
C 5 8 H 7 7 O N N 1 5 X 3 CH 3 COOH 
(1268.3) 
17.9 17.7 
Arg 1.8 Pro 1.02 Pip 1.8 
Gly 1.0 Phe 1.97 Ser 0.83 
138—140 
190—198 
- 3 4 ° D 
- 5 8 ° A 
C6 6H8 1 OIGN18 
(1433.5) 
c „ H75 o „ N15 X 3 CH3 COOH 
(1254.3) 
17.6 17.4 
Arg 1.9 Pro 2.0 Pip 0.9 . 
Gly 1.0 Phe 2.1 Ser 0.9 
134—138 
190—200 
- 3 4 ° D 
- 5 8 ° A 
C6(;H84 0 1 9 N 1 8 
(1433.5) 
c 5 7 H75 o „ N15 X 3 CH3 COOH 
(1254.3) 
17.6 17.4 
Arg 1.84 Pro 1.86 Pip 0.8 
Gly 1.0 Phe 1.88 Ser 0.91 
140—150 
168—178 
- 4 7 ° D 
- 8 0 ° A 
CßßHgj O19 Njg 
(1433.5) 
C S 7 H 7 5 0 „ N 1 5 X 3 CH 3 COOH 
(1254.3) 
17.6 17.5 
Arg 1.81 Pro 1.86 Pip 0.9 
Gly 1.0 Phe 1.96 Ser 0.8 
125—136 
165—175 
- 4 8 ° D 
- 7 6 ° A 
C 6 1H 8 3O 1 7N 7 
(1326.5) 
C 5 8 H 7 7 O N N 1 5 X 3 CH 3 COOH 
(1268.3) 
17.9 17.6 
Arg 1.82 Pro 0.9 Pip 1.8 
Gly 1.0 Phe 1.98 Ser 0.88 
117—124 
191—200 
- 4 0 ° D 
- 8 2 ° A 
C„8H8 8O1 9N1 8 
(1461.6) 
C 5 9 H 7 9 O N N 1 5 x 3 CH 3 COOH 
(1282.4) 
17.2 17.1 
Arg 1.87 Pip 2.79 
Gly 1.0 Phe 2.04 Ser 0.81 
Experimental 
Melting points were determined with a Kofler-block and optical rotations 
with a Zeiss-polarimeter. Amino acid analysis was performed on a Czechoslovakian 
HD-1200 E analyser after hydrolysis in 6 N HC1. 
IR spectra were taken in KBr on a Unicam SP 200 instrument. TLC on Kiesel 
G plates was used for purity control and identification in the following systems: 
1. n-butanol—acetic acid—water 4:1:1 
7* 
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2. ethyl acetate—pyridine—acetic acid—water 60:20:6:11 
3. ethyl acetate—pyridine—acetic acid—water 80:20:6:11 
4. ethyl acetate—pyridine—acetic acid—water 90:20:6:11 
5. chloroform—methanol 8:2 
6. chloroform—methanol—acetic acid 85:10:5. 
The protected analogues were purified on a Merck Kieselgel 60 (0.063—0.2) 
•column, eluted with system 2 or 3 or with ethyl acetate—methanol. The free peptides 
were purified by ion-exchange chromatography on a Whatman CM 32 carboxy-
methyl-cellulose column, eluted with a 0.01—0.5 M ammonium acetate gradient. 
Development of the TLC was carried out with ninhydrin, chlorine/o-toluidine and 
iSakaguchi reagent. 
All data of described analogues can be found in Table I. 
Methyl benzyloxycarbonvl-arginyl(nitro)-L-pipecolyl-prolyl-glycyl-
phenylalanyl-seryl-L-pipecolyl-phenylalanyl-nitroargininate (1) 
1.37 g (1.5 mmole) protected octapeptide ester [19] was treated with excess of 
•trifluoroacetic acid at room temperature for 1 hour. The acid was evaporated in 
vacuum and the remaining trifluoroacetate cf the octapeptide ester precipitated 
with ether, filtered, and dissolved in 8 ml dimethylformamide, cooled to — 5 °C, 
:and neutralized with triethylamine. 389 mg (1.65 mmole) benzyloxycarbonyl-(nitro)ar-
ginine was added, followed by 190 mg (1.65 mmole) N-hydroxysuccinimide (HOSu) 
and 310 mg (1.5 mmole) dicyclohexylcarbodiimide (DCCI). The reaction mixture 
was stirred at 0°C for 4 hr, and then at room temperature for 24 hr. After filtering 
off the dicyclohexylurea, the filtrate was evaporated in vacuum, and the residue 
was triturated with ether, washed in turn with water, acetone and ether, and dis-
solved in methanol for column chromatography. The fractions were evaporated 
nn vacuum, triturated in ether and dried. 
Arginyl-L-pipecolyl-prolyl-glycyl-phenylalanyl-seryl-L-pipecolyl-
phenylalanyl-arginine triacetate (2) 
620 mg (1) was dissolved in dioxan—methanol 5:1, and 0.5 ml 2 N NaOH 
was added. After a 4-hr stirring at room temperature, 0.5 ml 2 N H2S04 was added, 
and the mixture was evaporated in vacuum till half volume, poured into ice-water, 
filtered and washed with ether. The residual powder was dissolved in acetic acid— 
methanol 3:1, and the solution was hydrogenated in the presence of 10% Pd-C 
and Pd-black catalysts in a bubbling-apparatus at room temperature. The catalysts 
were filtered off and the filtrate was evaporated in vacuum. The residue was dissolved 
in start buffer (pH 5) and chromatographed. The main peak was collected and 
Jiophilized. The latter process was repealed Hvice from dilute acetic acid and water. 
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Methyl benzyloxycarbonyl-arginyl(nitro) -prolyl-L-pipecolyl-glycyl-
phenylalanyl-seryl-L-pipeco/yl-phenyialanyl nitroargininate (3) 
1.0 g (1.0 mmole) protected octapeptide ester [19] was treated with trifluoro-
acetic acid, and the trifluoroacetate of the octapeptide ester, coupled with benzyl-
oxycarbonyl(nitro)arginine in the presence of HOSu and DCCI, was worked up-
and chromatographed as described for (1). 
A rginyl-prolyl-L-pipecolyl-glycyl-phenylalanyl-seryl-L-pipecolyl-
phenylalanyl-arginine triacetate (4) 
150 mg (3) was hydrolyzed, hydrogenated, chromatographed and worked up-
as described for (2). 
p-Nitrobenzyl benzyloxycarbonyl-arginyl(nitro)-D-pipecolylproIyl-glycyl-
phenylalanyl-seryl-prolyl-phenylalanyl-nitro-nitroargininate (5) 
1.2 g (1.0 mmole) protected octapeptide ester [19] was treated with trifluoro-
aeetic acid, and the trifluoroacetate of the octapeptide ester, coupled with benzyl-
oxycarbonyl-(nitro)arginine in the presence of HOSu and DCCI, was worked up 
as described for (1), chromatographed in ethyl acetate—methanol and worked 
up similarly. 
Arginyl-D-pipecolyl-prolyl-glycyl-phenylalanyl-seryl-prolyl-phenylalanyl-
arginine triacetate (6) 
143 mg (5) was hydrogenated as described for (2) (but only in the presence-




1.2 g (1.0 mmole) protected octapeptide ester [19] was treated with trifluoro-
acetic acid, and the trifluoroacetate of the octapeptide ester, coupled with benzyl-' 
oxycarbonyl-(nitro)arginine in the presence of HOSu and DCCI, was worked up-
as described for (1), with chromatography in ethyl acetate—methanol as for (5).. 
Arginyl-prolyl-prolyl-glycyl-phenylalanyl-seryl-p-pipecolyl-
phenylalanyl-arginine triacetate (8) 
380 mg (7) was hydrogenated, chromatographed, and worked up as described< 
for (6). 
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p-Nitrobenzyl benzyloxycarbonyl-arginyl(nitro) -prolyl-glycyl-phenylalanyl-
seryl-L-pipecolyl-phenylalanyl-nitroargininate (9) 
1.54 g (1.5 mmole) protected hexapeptide ester [19] was dissolved in acetic 
acid — HBr. After 1 hr the solution was evaporated in vacuum, solidified with 
ether, washed with ether and dried. The crude product hydrobromide of the hexa-
peptide ester was dissolved in dimethylformamide, cooled to —15 °C and neutralized 
with N-methyl morpholine. From 840 mg benzyloxycarbonyl-arginyl(nitro)-prolyl-
proline the azide was prepared in situ at — 15°C. The two cooled solutions were 
poured together and stirred for 48 hr at 0°C, and then filtered, evaporated in 
vacuum, dissolved for chromatography, and worked up as described for (5). 
Arginyl-prolyl-prolyl-glycyl-phenylalanyi-seryl-L-pipecolyl-phenylalanyl-
arginine triacetate (10) 




1.35 g (1.5 mmole) protected hexapeptide ester [19] was treated with acetic 
acid—HBr, and the hydrobromide of the hexapeptide ester, coupled with 864 mg 
benzyloxycarbonyl-arginyl(nitro)-L-pipecolyl-L-pipecolic acid (converted in situ to 
the azide), and worked up and chromatographed as described for (9). 
Arginyl-L-pipecolyl-L-pipecolyl-glycyl-phenylalanyl-seryl-propyl-
phenylalanyl-arginine triacetate (12) 




1.56 g (1.5 mmole) protected hexapeptide ester [19] was treated with acetic 
acid — HBr, and the hydrobromide of the hexapeptide ester, coupled with 864 mg 
benzyloxycarbonyl-arginyl(nitro)-L-pipecolyl-L-pipecolic acid (converted in situ to 
the azide), and worked up and chromatographed as described for (9). 
Arginyl-L-pipecolyl-L-pipecolyl-glycyl-phenyla!anyl-seryl-L-pipecoIyl-
phenylalanyl-arginine triacetate 14 
700 mg (13) was hydrogenated, chromatographed, and worked up as described 
for (6). 
* * * 
SYNTHESIS OF BRADYKININ ANALOGUES 185 
The authors are indebted to thanks to the microanalytical and infrared laboratory 
of the Organic Chemistry Institute of Attila József University, Szeged, for elemental 
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СИНТЕЗ АНАЛОГОВ БРАДИКИНИНА, СОДЕРЖАЩИХ 
ПИПЕКОЛИНОВУЮ КИСЛОТУ 
Я. Балашпири, Дь. Папп, М. Тот, Ф. Широкман и К. Ковач 
Описан синтез, очистка и физические характеристики аналогов брадикинина, содержащих 
оптически активную — L- и о-пипеколиновую кислоту. 
